Photobiomodulation as part of multimodal analgesia to improve pain relief and wound healing after elective caesarean section: A protocol for randomized controlled trial.

Autor: Khaled M; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.; Perioperative and Surgery Research Program, Population Health Research Institute, Hamilton, Ontario, Canada., Baranov A; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Diaz A; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Patel M; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Clements S; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Farsinejad P; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Khatana K; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Gnanapragasam A; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Selvanayagam S; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Muhsen Z; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada., Chan J; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada., Hunjan S; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada., Kazi A; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Sharma S; Department of Obstetrics & Gynecology, McMaster University, Hamilton, Ontario, Canada., Luketic L; Department of Obstetrics & Gynecology, McMaster University, Hamilton, Ontario, Canada., Ewusie JE; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.; The Research Institute of St. Joes Hamilton, Hamilton, Ontario, Canada., Cordovani D; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada., Shanthanna H; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.

Publikováno v: PloS one [PLoS One] 2024 Dec 26; Vol. 19 (12), pp. e0314010. Date of Electronic Publication: 2024 Dec 26 (Print Publication: 2024).

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.

Autor: O'Brien Gore C; School of Cancer and Pharmaceutical Sciences, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK., Billman A; Analytical Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Hunjan S; Oncology Cell Therapy Unit, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Colebrook J; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Choy D; School of Cancer and Pharmaceutical Sciences, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK., Li W; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Haynes J; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Wade J; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Hobern E; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., McDonald L; Oncology & Hematology Clinical Trials (OHCT), Guy's Hospital, 1st Floor Chapel Wing, Great Maze Pond, SE1 9RT London, UK., Papa S; School of Cancer and Pharmaceutical Sciences, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK., Brugman M; Analytical Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK., Kordasti S; School of Cancer and Pharmaceutical Sciences, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK., Montiel-Equihua C; Product Development, Cell and Gene Therapy, GSK Medicine Research Centre, Stevenage, SG1 2NY Hertfordshire, UK.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Nov 10; Vol. 31, pp. 100749. Date of Electronic Publication: 2023 Nov 10 (Print Publication: 2023).

Three-dimensional (3D) anatomic location, extension, and timing of severe osteoradionecrosis of the mandible.

Autor: Sapienza LG; Department of Radiation Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States., Thomas JJ; Department of Radiation Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States., Mai W; Department of Radiation Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States.; Department of Radiation Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States., Hanania AN; Department of Radiation Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States., Hunjan S; Department of Radiation Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States., Sandulache VC; ENT Section - Operative Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States.; Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, United States., Chen AC; Department of Radiation Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States.; Department of Radiation Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States.

Publikováno v: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2022 Jul 29; Vol. 27 (3), pp. 519-526. Date of Electronic Publication: 2022 Jul 29 (Print Publication: 2022).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EPIC: A NON‐INTERVENTIONAL, OBSERVATIONAL UK STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH FIRST‐LINE ACALABRUTINIB. INTERIM ANALYSIS UP TO 24 MONTHS.

Autor: Eyre, T. A., Martinez‐Calle, N., Walewska, R., Hickey, J., Blak, B. T., Pickin, A., Hunjan, S., Condon, O., Hori, S.

Publikováno v: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p737-738, 2p